Evidence map›Paper›PMID 42397484›Full record

ReviewClinical reviews in allergy & immunology2026

Therapeutic Targeting of the Bradykinin B2 Receptor in Immunological and Vascular Diseases: Insights from Kinin Biology to Clinical Outcomes.

Marc A Riedl, Danny M Cohn, Markus Magerl, Henriette Farkas, Emel Aygören-Pürsün, Aleena Banerji, Jonathan A Bernstein, Alvin H Schmaier, Evangelia Pardali, Anne Lesage and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marc A Riedl *Division of Allergy and Immunology, University of California, La Jolla, San Diego, CA, USA. mriedl@ucsd.edu.
Danny M Cohn *Amsterdam UMC, Department of Vascular Medicine, University of Amsterdam, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
Markus MagerlInstitute of Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology, Immunology and Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universitätsmedizin Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Henriette FarkasHungarian Angioedema Center of Reference and Excellence, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Emel Aygören-PürsünDepartment for Children and Adolescents, Goethe University Frankfurt, Frankfurt, Germany.
Aleena BanerjiDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, USA.
Jonathan A BernsteinDivision of Rheumatology, Allergy and Immunology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Alvin H SchmaierDivision of Hematology and Oncology, Department of Medicine, Case Western Reserve University, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Evangelia PardaliPharvaris BV, Leiden, The Netherlands.
Anne LesageGrayMatters Consulting, Schilde, Belgium.
Peng LuPharvaris Inc, Lexington, MA, USA.
David E NewbyBritish Heart Foundation Centre of Research Excellence, University of Edinburgh, Edinburgh, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bradykinin is a nonapeptide of the kinin family with vasoactive and proinflammatory activities. While generation of kinins is mainly driven by activation of the contact system and plasma or tissue kallikreins, additional independent cascades contribute to their formation. Kinins mediate their effects through the constitutively expressed bradykinin B2 receptor and the inducible bradykinin B1 receptor. Bradykinin is the most studied kinin peptide mainly due to its potential role in the vascular system and exerts its effects mainly via the bradykinin B2 receptor. Kinins have been implicated in the pathogenesis of multiple types of angioedema as well as of various conditions, such as allergic mast cell-mediated skin diseases, cardiovascular and respiratory pathologies. This review summarizes our current knowledge of the biology, regulation, and functions of kinins and their receptors as well the emerging evidence on the various mechanisms involved in bradykinin formation and their relevance in disease pathogenesis. The review focuses on the clinical evidence on the roles of bradykinin and of the bradykinin B2 receptor in various conditions, and the potential to develop novel strategies targeting the bradykinin B2 receptor for management of bradykinin-mediated diseases.

Indexed as

Bradykinin B2 Receptor AntagonistsImmune System DiseasesKininsReceptor, Bradykinin B2Vascular DiseasesAnimalsBradykininHumansMolecular Targeted TherapySignal TransductionBradykininBradykinin B2 Receptor AntagonistsKininsReceptor, Bradykinin B2AngioedemaBradykininBradykinin B2 receptorBradykinin-mediated angioedemaBradykinin receptorCardiovascularVascular biology

Identifiers

PMID42397484
PMCPMC13331952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.